Related references
Note: Only part of the references are listed.A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic study
Michael T. Furlong et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2012)
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
A. Kreutzman et al.
LEUKEMIA (2011)
Integration of Activating and Inhibitory Receptor Signaling by Regulated Phosphorylation of Vav1 in Immune Cells
Sven Mesecke et al.
SCIENCE SIGNALING (2011)
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
Andreas Lundqvist et al.
JOURNAL OF CANCER (2011)
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
Anna Kreutzman et al.
BLOOD (2010)
The BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib differentially affect NK cell reactivity
Julia Salih et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo
Cara K. Fraser et al.
EXPERIMENTAL HEMATOLOGY (2009)
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Dong Hwan Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Permanent silencing of NKG2A expression for cell-based therapeutics
Constanca Figueiredo et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Stephen J. Blake et al.
BLOOD (2008)
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
Michael Brave et al.
CLINICAL CANCER RESEARCH (2008)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions
Katrin M. Baltz et al.
FASEB JOURNAL (2007)
Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells
Mostafa Jarahian et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
CD56dimCD16+ NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases
B. Grzywacz et al.
LEUKEMIA (2007)
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity
VR Gómez-Román et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion
YT Bryceson et al.
BLOOD (2006)
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells
YT Bryceson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D
K Eleme et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
CD107a as a functional marker for the identification of natural killer cell activity
G Alter et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Syk regulation of phosphoinositide 3-kinase-dependent NK cell function
K Jiang et al.
JOURNAL OF IMMUNOLOGY (2002)
Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells
C Ramoni et al.
JOURNAL OF IMMUNOLOGY (2001)
Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells
K Jiang et al.
NATURE IMMUNOLOGY (2000)
RAC1/P38 MAPK signaling pathway controls beta 1 integrin-induced interleukin-8 production in human natural killer cells
F Mainiero et al.
IMMUNITY (2000)
Share Paper
